Advertisement

The Role of Complement in the Antiphospholipid Syndrome-Associated Pathology

  • Ingrid Avalos
  • George C. Tsokos
Article

Abstract

The antiphospholipid syndrome (APS) is characterized by arterial and/or venous thromboses, pregnancy loss, and the presence of anticardiolipin antibodies. The pathogenic mechanisms that lead to these clinical manifestations are incompletely understood. Although a direct pathogenic role of antiphospholipid antibodies has been established, including their role in endothelial cell and platelet activation, there is growing evidence that activation of the complement pathway may contribute to the pathogenesis of APS. Vital information has been obtained from studies exploring the features of pregnancy morbidity and thrombosis using complement deficient murine models. These studies are providing the foundation for the development of new therapeutic options to optimize the management of APS.

Keywords

Complement Antiphospholipid Pregnancy loss Thrombosis 

References

  1. 1.
    Kim YU, Kinoshita T, Molina H et al (1995) Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med 181(1):151–159, January 1PubMedCrossRefGoogle Scholar
  2. 2.
    Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H (2000) A critical role for murine complement regulator crry in fetomaternal tolerance. Science 287(5452):498–501, January 21PubMedCrossRefGoogle Scholar
  3. 3.
    Lockshin MD, Sammaritano LR, Schwartzman S (2000) Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 43(2):440–443, FebruaryPubMedCrossRefGoogle Scholar
  4. 4.
    Holers VM, Girardi G, Mo L et al (2002) Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 195(2):211–220, January 21PubMedCrossRefGoogle Scholar
  5. 5.
    Girardi G, Berman J, Redecha P et al (2003) Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112(11):1644–1654, DecemberPubMedGoogle Scholar
  6. 6.
    Kirchhofer D, Moran P, Bullens S, Peale F, Bunting S (2005) A monoclonal antibody that inhibits mouse tissue factor function. J Thromb Haemost 3(5):1098–1099, MayPubMedCrossRefGoogle Scholar
  7. 7.
    Pawlinski R, Pedersen B, Erlich J, Mackman N (2004) Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb Haemost 92(3):444–450, SeptemberPubMedGoogle Scholar
  8. 8.
    Shamonki JM, Salmon JE, Hyjek E, Baergen RN (2007) Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 196(2):167.e1–167e.5, FebruaryCrossRefGoogle Scholar
  9. 9.
    Stone S, Pijnenborg R, Vercruysse L et al (2006) The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 27(4-5):457–467, AprilPubMedCrossRefGoogle Scholar
  10. 10.
    Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J (2005) Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 52(7):2120–2124, JulyPubMedCrossRefGoogle Scholar
  11. 11.
    Oku K, Atsumi T, Bohgaki M et al (2008) Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis, July 14. doi: 10.1136/ard.2008.090670
  12. 12.
    Peerschke EI, Yin W, Grigg SE, Ghebrehiwet B (2006) Blood platelets activate the classical pathway of human complement. J Thromb Haemost 4(9):2035–2042, SeptemberPubMedCrossRefGoogle Scholar
  13. 13.
    Simpson R, Alon R, Kobzik L, Valeri CR, Shepro D, Hechtman HB (1993) Neutrophil and nonneutrophil-mediated injury in intestinal ischemia-reperfusion. Ann Surg 218(4):444–453, OctoberPubMedCrossRefGoogle Scholar
  14. 14.
    Crawford MH, Grover FL, Kolb WP et al (1988) Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 78(6):1449–1458, DecemberPubMedGoogle Scholar
  15. 15.
    Carter RH, Fearon DT (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256(5053):105–107, April 3PubMedCrossRefGoogle Scholar
  16. 16.
    Fleming SD, Shea-Donohue T, Guthridge JM et al (2002) Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol 169(4):2126–2133, August 15PubMedGoogle Scholar
  17. 17.
    Fleming SD, Egan RP, Chai C et al (2004) Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol 173(11):7055–7061, December 1PubMedGoogle Scholar
  18. 18.
    Williams JP, Pechet TT, Weiser MR et al (1999) Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol 86(3):938–942, MarchPubMedGoogle Scholar
  19. 19.
    Stahl GL, Xu Y, Hao L et al (2003) Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol 162(2):449–455, FebruaryPubMedGoogle Scholar
  20. 20.
    Derksen RH, Khamashta MA, Branch DW (2004) Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 50(4):1028–1039, AprilPubMedCrossRefGoogle Scholar
  21. 21.
    Edens RE, Linhardt RJ, Bell CS, Weiler JM (1994) Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacology 27(2):145–153, MarchPubMedCrossRefGoogle Scholar
  22. 22.
    Weiler JM, Edens RE, Linhardt RJ, Kapelanski DP (1992) Heparin and modified heparin inhibit complement activation in vivo. J Immunol 148(10):3210–3215, May 15PubMedGoogle Scholar
  23. 23.
    Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF (1981) Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 67(1):223–228, JanuaryPubMedCrossRefGoogle Scholar
  24. 24.
    Girardi G, Redecha P, Salmon JE (2004) Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10(11):1222–1226, NovemberPubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  1. 1.Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA

Personalised recommendations